SUZ12 encodes a core subunit of Polycomb Repressive Complex 2 (PRC2), which functions as a critical epigenetic regulator by methylating histone H3 at lysines 9 and 27 (H3K9me and H3K27me3), leading to transcriptional repression of target genes 1. The protein serves as a scaffold that enables assembly of distinct histone modification complexes, coordinating chr17 remodeling activities 1. SUZ12 plays essential roles in controlling developmental timing by maintaining chr17 bivalency at developmental gene promoters - loss of SUZ12 function accelerates cell fate acquisition by shifting the balance between activating H3K4me3 and repressive H3K27me3 marks 2. SUZ12 can translocate from mitochondria to nucleus where it interacts with other PRC2 components to regulate gene expression pathways including STAT3 signaling 3. Germline heterozygous variants in SUZ12 cause Imagawa-Matsumoto syndrome, characterized by overgrowth and dysmorphic features 4. In cancer, SUZ12 alterations contribute to malignant progression - fusion proteins like JAZF1-SUZ12 dysregulate PRC2 function in endometrial stromal sarcomas 5, while SUZ12 mutations in malignant peripheral nerve sheath tumors lead to loss of H3K27 trimethylation 6. These findings establish SUZ12 as a crucial regulator of development, differentiation, and tumorigenesis through chr17-mediated gene silencing.